MacroGenics, Inc. (NASDAQ:MGNX) Shares Purchased by Frazier Life Sciences Management L.P.

Frazier Life Sciences Management L.P. raised its stake in shares of MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 5.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,175,665 shares of the biopharmaceutical company's stock after purchasing an additional 164,938 shares during the period. Frazier Life Sciences Management L.P. owned 5.06% of MacroGenics worth $10,321,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the stock. Lazard Asset Management LLC acquired a new position in shares of MacroGenics during the 4th quarter worth about $32,000. American Century Companies Inc. purchased a new stake in MacroGenics during the 4th quarter worth approximately $38,000. Jump Financial LLC purchased a new stake in MacroGenics during the 4th quarter worth approximately $44,000. ProShare Advisors LLC raised its holdings in shares of MacroGenics by 32.4% during the fourth quarter. ProShare Advisors LLC now owns 20,284 shares of the biopharmaceutical company's stock valued at $66,000 after acquiring an additional 4,963 shares during the last quarter. Finally, XML Financial LLC lifted its position in shares of MacroGenics by 31.6% in the fourth quarter. XML Financial LLC now owns 23,169 shares of the biopharmaceutical company's stock valued at $75,000 after acquiring an additional 5,569 shares in the last quarter. Institutional investors and hedge funds own 96.89% of the company's stock.

MacroGenics Trading Down 4.4%

NASDAQ:MGNX traded down $0.07 during trading hours on Monday, hitting $1.51. The company had a trading volume of 273,887 shares, compared to its average volume of 799,201. MacroGenics, Inc. has a 1 year low of $0.99 and a 1 year high of $5.77. The company has a market cap of $95.27 million, a P/E ratio of -0.96 and a beta of 2.20. The company has a 50-day moving average of $1.49 and a 200 day moving average of $2.51.

MacroGenics (NASDAQ:MGNX - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.04). MacroGenics had a negative net margin of 69.07% and a negative return on equity of 89.42%. The firm had revenue of $13.19 million during the quarter, compared to analysts' expectations of $9.59 million. On average, analysts forecast that MacroGenics, Inc. will post -1.06 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently commented on MGNX shares. Wall Street Zen cut MacroGenics from a "hold" rating to a "sell" rating in a research report on Thursday. Stifel Nicolaus lowered their target price on shares of MacroGenics from $6.00 to $5.00 and set a "hold" rating on the stock in a research note on Wednesday, May 14th. Barclays reaffirmed an "overweight" rating and set a $3.00 target price (down previously from $8.00) on shares of MacroGenics in a report on Wednesday, May 14th. B. Riley decreased their price target on shares of MacroGenics from $5.00 to $3.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 20th. Finally, HC Wainwright lowered their price target on shares of MacroGenics from $4.00 to $2.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 25th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $5.71.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.